A Phase II Study of Single Agent MEK162 in Patients With Advanced Melanoma
A Phase II Study of Single Agent MEK162 in Patients With Advanced Melanoma
NCT ID: NCT01320085 Phase: PHASE2 Status: COMPLETED Enrollment: 183 Completion: 2023-02-06
Conditions
BRAF or NRAS Mutant Metastatic Melanoma
Interventions
MEK162
Summary
The study will assess the safety and efficacy of single-agent MEK162 in adult patients with locally advanced and unresectable or metastatic malignant cutaneous melanoma, harboring BRAFV600E or NRAS mutations.
Primary Outcome
Percentage of Participants With Objective Response (OR)